Neuland Laboratories Ltd.
Snapshot View

1028.35 +4.40 ▲0.4%

20 May 2022, 04:01:00 PM
Volume: 3,283

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.neulandlabs.com
Market Cap 1,317.31 Cr.
Enterprise Value(EV) 1,529.95 Cr. 2022-03
Financial Indicators
Earnings per share (EPS) 49.74 Trailing Twelve Months Ending 2022-03
Price-Earning Ratio (PE) 20.67 Trailing Twelve Months Ending 2022-03
Industry PE 29.26 Trailing Twelve Months Ending 2022-03
Book Value / Share 654.40 Trailing Twelve Months Ending 2022-03
Price to Book Value 1.57 Calculated using Price: 1,028.35
Dividend Yield 0.49 Period Ending 2021-03
No. of Shares Subscribed 1.28 Cr. 12,829,889 Shares
FaceValue 10
Company Profile

Named after Father Nieuwland of Notre dame, Neuland Laboratories was incorporated in 1984 by Dr. D. R. Rao for the manufacture of Salbutamol Sulphate, with mere 40 employees.

It has started its commercial production of Salbutamol Sulphate in the year 1986. It has since grown to become one of the most reliable API source for Pharma Industry with addition of more products in course of years.

Today the company with a total employee strength of 1000+ is the preferred supplier of APIs with unmatched quality and timely delivery. Neuland is a quality conscious, research driven, reliable source of active pharmaceutical ingredients.

Operating from India for over two decades, Neuland is the preferred source for the Pharmaceutical Industry across the globe, with strengths in Research based Chemistry and Manufacturing.

The Company has started its commercial production of Salbutamol Sulphate in the year 1986. It has since grown to become one of the most reliable API source for Pharma Industry with addition of more products in course of years.Today the company with a total employee strength of 1000+ is the preferred supplier of APIs with unmatched quality and timely delivery.

Neuland has two world-class API manufacturing facilities close to the city of Hyderabad, capable in handling complex and hazardous reactions. Safety aspects have been given utmost significance may it be plant installation, equipment, systems and personnel to ensure smooth productivity. Dedicated team of manufacturing with incorporation of latest production techniques guarantees delivery of latest intermediate and product to our customers across the globe.

Product range of the company includes:

  • Anti -Asthmatics
  • Fluoroquinolones
  • Cardiovascular
  • CNS
  • Corticosteroids
  • Anti-Ulcerant
  • Anti-Fungal
  • Anti-Parkinsons
  • Anti-Alzheimers

Achievements/ recognition:

  • Received a string of regulatory approvals from USFDA & EDQM for its major products (e.g., Ciprofloxacin HCl, Salbutamol Sulphate) USFDA systems inspection for its pashamylaram Facility (Unit-II) in the year 1999
  • USFDA systems inspection for its Bonthapally (Unit-I) bringing both facilities under full cGMP compliance in 2004
  • Received cGMP clearance for both facilities from TGA, Australia in 2004.
  • Certificate of suitability for product itraconazole in 2006.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+0.43%
1 Week
-1.20%
1 Month
-26.53%
3 Month
-8.59%
6 Month
-39.34%
1 Year
-54.46%
2 Year
+150.39%
5 Year
-27.08%
10 Year
+1401.90%
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 15.92 24.14 11.24 15.64 22.34 5.02 3.48 2.30 10.79
Return on Capital Employed (%) 15.58 18.99 15.75 18.57 15.98 4.07 3.99 7.85 12.81
Return on Assets (%) 3.26 5.89 3.20 5.23 6.65 1.23 1.49 1.37 6.31

Balance Sheet View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03* Rs. Cr.
Shh. Funds 100 124 161 187 546 558 699 710 786 841
Non Curr. Liab. 62 52 55 69 54 146 104 163 170 180
Curr. Liab. 263 307 295 268 286 367 327 358 369 363
Minority Int. 0 0 0
Equity & Liab. 425 483 512 524 886 1,071 1,130 1,231 1,325 1,383
Non Curr. Assets 198 196 196 210 511 624 677 716 775 801
Curr. Assets 227 288 316 314 375 447 453 515 550 583
Misc. Exp. not W/O
Total Assets 425 483 512 524 886 1,071 1,130 1,231 1,325 1,383

Profit Loss View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. TTM
Net Sales 461 466 469 510 579 527 667 763 937 951
Other Income 4 3 1 2 1 5 3 4 16 5
Total Income 465 469 470 512 580 532 670 767 953 956
Total Expenditure -403 -395 -403 -430 -473 -477 -608 -661 -790 -811
PBIDT 62 74 67 82 108 55 62 106 163 145
Interest -31 -25 -27 -24 -21 -19 -16 -22 -18 -14
Depreciation -15 -15 -15 -16 -19 -22 -26 -31 -40 -49
Taxation -2 -8 -9 -15 -20 -2 -4 -37 -25 -18
Exceptional Items
PAT 14 27 16 27 47 12 16 16 81 64
Minority Interest 0 0 0 0
Share Associate
Other Related Items
Consolidated Net Profit 14 27 16 27 47 12 16 16 81 64
Adjusted EPS 17 33 18 31 53 14 13 13 63 49

Cash Flow View Details

Particulars 10 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 49 26 49 13 45 39 11 70 57 189
Cash Fr. Inv. -5 -7 -10 -14 -20 -42 -116 -77 -49 -84
Cash Fr. Finan. -44 -20 -39 1 -24 0 105 12 -5 -114
Net Change 0 -1 0 0 1 -4 0 5 3 -9
Cash & Cash Eqvt 2 1 1 1 2 3 3 8 11 2

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 36.20 36.27 36.25 36.25 36.22 36.22 36.22 36.22 36.22
Public 63.80 63.73 63.75 63.75 63.78 63.78 63.78 63.78 63.78
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 4.31 4.30 4.30 4.30 4.30 4.30 4.30 4.30 0.00

Announcements View Details

Thu, 19 May 2022
Compliances-Reg.24(A)-Annual Secretarial Compliance
Reg.24A-Annual Secretarial Compliance Report for the year ended March 31 2022
Wed, 11 May 2022
Announcement under Regulation 30 (LODR)-Newspaper Publication
Neuland Laboratories Limited has informed the Exchange about Newspaper Advertisements
Tue, 10 May 2022
Board Meeting Outcome for Outcome Of Board Meeting Audited Results And Recommendation Of Final Dividend For The Year Ended March 31 2022
Outcome of Board Meeting Audited results and recommendation of final dividend for the year ended March 31 2022

Technical Scans View Details

Fri, 20 May 2022
Close Within 52 Week Low Zone Close Within 52 Week Low Zone
High Decrease 1 Month High Decrease 1 Month
High Decrease 6 Months High Decrease 6 Months
High Decrease 1 Year High Decrease 1 Year
High Increase 2 Years High Increase 2 Years

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 219,659.12 915.50 +3.5%
Divi's Laboratories Ltd. 114,020.08 4,295.05 +2.2%
Cipla Ltd. 78,954.82 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. 70,669.41 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. 52,783.35 3,671.00 +1.0%
Gland Pharma Ltd. 50,388.39 3,061.70 -1.1%
Piramal Enterprises Ltd. 45,754.22 1,917.10 +1.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 34.09 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-12 44.40 4,295.05 +2.2%
Cipla Ltd. Consolidated 2022-03 31.37 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 32.38 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 46.57 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2022-03 41.59 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-12 36.83 1,917.10 +1.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.25 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-12 10.53 4,295.05 +2.2%
Cipla Ltd. Consolidated 2022-03 3.79 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.68 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 9.54 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2022-03 7.04 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-12 1.29 1,917.10 +1.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 0.10 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 0.00 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 1,917.10 +1.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 14.13 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,917.10 +1.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 14.13 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,917.10 +1.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 19,159.59 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 1,917.10 +1.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 2,401.30 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 996.96 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 1,917.10 +1.2%